Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22867132 | 1.00 | NLRP3 (0.43) | NLRP3PTGESTDO2MTNR1AMTNR1B | |
| SCHEMBL22773915 | 0.87 | NLRP3 (0.54) | NLRP3MTNR1AMTNR1B | |
| SCHEMBL22866904 | 0.86 | NLRP3 (0.46) | NLRP3PTGESTDO2MKNK1MKNK2 | |
| SCHEMBL22802393 | 0.82 | NLRP3 (0.49) | NLRP3MTNR1AMTNR1B | |
| SCHEMBL30163219 | 0.82 | NLRP3 (0.49) | NLRP3MTNR1AMTNR1B | |
| SCHEMBL25067001 | 0.82 | MTNR1A (0.46) | NLRP3MTNR1AMTNR1B | |
| SCHEMBL29691425 | 0.81 | NLRP3 (0.42) | NLRP3 | |
| SCHEMBL23012387 | 0.81 | NLRP3 (0.42) | NLRP3 | |
| SCHEMBL22866885 | 0.79 | NLRP3 (0.43) | NLRP3 | |
| SCHEMBL19475243 | 0.78 | MTNR1A (0.42) | NLRP3MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | NLRP3 1/4885PTGES 2455/4885TDO2 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.